You just read:

Health Canada Approves Ipsen's CABOMETYX™ (cabozantinib) Giving Physicians and Patients a Novel Second-Line Option in the Fight Against Advanced Renal Cell Carcinoma

News provided by

Ipsen Biopharmaceuticals Canada Inc.

Sep 19, 2018, 07:30 ET